Cyclophosphamide
- Generic Name
- Cyclophosphamide
- Brand Names
- Procytox
- Drug Type
- Small Molecule
- Chemical Formula
- C7H15Cl2N2O2P
- CAS Number
- 50-18-0
- Unique Ingredient Identifier
- 6UXW23996M
- Background
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
- Indication
Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
- Associated Therapies
- -
A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma
- Conditions
- Alveolar RhabdomyosarcomaBotryoid-Type Embryonal RhabdomyosarcomaEmbryonal RhabdomyosarcomaMetastatic Embryonal RhabdomyosarcomaMetastatic RhabdomyosarcomaSolid Alveolar RhabdomyosarcomaSpindle Cell RhabdomyosarcomaSpindle Cell/Sclerosing Rhabdomyosarcoma
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Bone ScanProcedure: Computed TomographyDrug: CyclophosphamideBiological: DactinomycinProcedure: Magnetic Resonance ImagingProcedure: Positron Emission TomographyRadiation: Radiation TherapyDrug: Vincristine SulfateDrug: Vinorelbine TartrateProcedure: X-Ray Imaging
- First Posted Date
- 2021-08-06
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 118
- Registration Number
- NCT04994132
- Locations
- πΊπΈ
Augusta University Medical Center, Augusta, Georgia, United States
πΊπΈChildren's Hospital of Alabama, Birmingham, Alabama, United States
πΊπΈUSA Health Strada Patient Care Center, Mobile, Alabama, United States
Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma
- Conditions
- Relapsed and/or Refractory B-cell Lymphoma
- Interventions
- First Posted Date
- 2021-08-04
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Kite, A Gilead Company
- Target Recruit Count
- 114
- Registration Number
- NCT04989803
- Locations
- πΊπΈ
Virginia Oncology Associates, Norfolk, Virginia, United States
π¦πΊRoyal North Shore Hospital, St Leonards, New South Wales, Australia
πΊπΈBanner MD Anderson Cancer Center, Gilbert, Arizona, United States
A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma
- Conditions
- Lymphoma
- Interventions
- First Posted Date
- 2021-07-28
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 46
- Registration Number
- NCT04980222
- Locations
- πͺπΈ
Hospital Clinico Universitario de Salamanca;Servicio de Hematologia, Salamanca, Spain
πΊπΈCity of Hope Comprehensive Cancer Center, Duarte, California, United States
πΊπΈStanford Cancer Center, Palo Alto, California, United States
Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- First Posted Date
- 2021-07-27
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT04978584
- Locations
- πΊπΈ
M D Anderson Cancer Center, Houston, Texas, United States
A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (LOTIS-8)
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- First Posted Date
- 2021-07-23
- Last Posted Date
- 2022-03-29
- Lead Sponsor
- ADC Therapeutics S.A.
- Registration Number
- NCT04974996
- Locations
- πΊπΈ
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies
- Conditions
- Hematologic Neoplasms
- Interventions
- Drug: Mycophenolate MofetilProcedure: Allogeneic HSCTDrug: FludarabineDrug: SirolimusDrug: FilgrastimDrug: CyclophosphamideDrug: MesnaProcedure: Total Body Irradiation (TBI)
- First Posted Date
- 2021-07-13
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 320
- Registration Number
- NCT04959175
- Locations
- πΊπΈ
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
πΊπΈNational Institutes of Health Clinical Center, Bethesda, Maryland, United States
A Study of N9 Chemotherapy in Children With Neuroblastoma
- Conditions
- Pediatric CancerNeuroblastoma
- Interventions
- First Posted Date
- 2021-07-01
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 26
- Registration Number
- NCT04947501
- Locations
- πΊπΈ
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Outcomes of Patients After Allo-HSCT With Decitabine and NAC
- Conditions
- Engraft FailureRelapseGVHD
- Interventions
- First Posted Date
- 2021-06-30
- Last Posted Date
- 2021-06-30
- Lead Sponsor
- The First Affiliated Hospital of Soochow University
- Target Recruit Count
- 100
- Registration Number
- NCT04945096
Post-transplantation Benadamustine and Cyclophosphamide in Patients With Refractory Myeloid Malignancies
- Conditions
- Chronic Myeloid LeukemiaMyeloproliferative NeoplasmMyeloid Leukemia, AcuteMyelodysplastic Syndromes
- Interventions
- First Posted Date
- 2021-06-29
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- St. Petersburg State Pavlov Medical University
- Target Recruit Count
- 50
- Registration Number
- NCT04943757
- Locations
- π·πΊ
RM Gorbacheva Research Institute, Saint Petersburg, Russian Federation
Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe)
- Conditions
- Leukemia, Acute LymphoblasticMyeloid Leukemia, AcuteMyelodysplastic SyndromesMyeloproliferative NeoplasmLymphoblastic LymphomaBiphenotypic Acute Leukemia
- Interventions
- First Posted Date
- 2021-06-28
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- St. Petersburg State Pavlov Medical University
- Target Recruit Count
- 50
- Registration Number
- NCT04942730
- Locations
- π·πΊ
RM Gorbacheva Research Institute, Saint Petersburg, Russian Federation
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.